High variability in glucocorticoid starting doses in patients with rheumatoid arthritis: observational data from an early arthritis cohort

Rheumatology International

Volumn 35, Issue 8, 2015, Pages 1377-1384

  Albrecht, Katinka ^a   Callhoff, Johanna ^a   Schneider, Matthias ^b   Zink, Angela ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Corticosteroids; Glucocorticoids; Rheumatoid arthritis; Treatment

Indexed keywords

BIOLOGICAL PRODUCT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; PRESCRIPTION DRUG; ANTIRHEUMATIC AGENT;

ADULT; AGE DISTRIBUTION; ARTICLE; BIOLOGICAL THERAPY; CLINICAL EVALUATION; COHORT ANALYSIS; COMORBIDITY; CORTICOSTEROID THERAPY; DAS28; DRUG DOSE INCREASE; DRUG MEGADOSE; FEMALE; FOLLOW UP; FUNCTIONAL STATUS ASSESSMENT; HANNOVER FUNCTIONAL STATUS QUESTIONNAIRE; HUMAN; INTERVENTION STUDY; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MUSCULOSKELETAL DISEASE ASSESSMENT; OBSERVATIONAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SEX RATIO; TIME TO TREATMENT; TREATMENT OUTCOME; TREATMENT RESPONSE; AGED; ARTHRITIS, RHEUMATOID; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION DRUG THERAPY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; OUTPATIENT DEPARTMENT; PRIVATE PRACTICE; PROFESSIONAL PRACTICE; PROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; LOGISTIC MODELS; MALE; METHOTREXATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OUTPATIENT CLINICS, HOSPITAL; PRACTICE PATTERNS, PHYSICIANS'; PREDNISOLONE; PRIVATE PRACTICE; PROFESSIONAL PRACTICE LOCATION; PROSPECTIVE STUDIES; RHEUMATOLOGY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84931576691     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-015-3229-x     Document Type: Article

References (25)

1. Smolen JS, Aletaha D, Machold KP (2005) Therapeutic strategies in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 19(1):163–177
2. van Nies JA, Krabben A, Schoones JW, Huizinga TW, Kloppenburg M, van der Helm-van Mil AH (2014) What is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review. Ann Rheum Dis 73(5):861–870
3. Smolen JS, Landewe R, Breedveld FC et al (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73(3):492–509
4. Albrecht K, Kruger K, Wollenhaupt J et al (2014) German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. Rheumatol Int 34(1):1–9
5. Singh JA, Furst DE, Bharat A et al (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64(5):625–639
6. NICE (National Institute for Health And Care Excellence) (August 2013) Rheumatoid Arthritis. The management of rheumatoid arthritis in adults. http://www.nice.org.uk/nicemedia/live/12131/43327/43327.pdf. Accessed Aug 2013
7. Duru N, van der Goes MC, Jacobs JW et al (2013) EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 72(12):1905–1913
8. Gaujoux-Viala C, Nam J, Ramiro S et al (2014) Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis 73(3):510–515
9. Rau R (2014) Glucocorticoid treatment in rheumatoid arthritis. Expert Opin Pharmacother 15(11):1575–1583
10. Boers M, van Tuyl PJ, van den Broek M, Kostense PJ, Allaart CF (2013) Meta-analysis suggests that intensive non-biological combination therapy with step-down prednisolone (COBRA strategy) may also ‘disconnect’ disease activity and damage in rheumatoid arthritis. Ann Rheum Dis 72(3):406–409
11. Montecucco C, Todoerti M, Sakellariou G, Scire CA, Caporali R (2012) Low-dose oral prednisone improves clinical and ultrasonographic remission rates in early rheumatoid arthritis: results of a 12-month open-label randomised study. Arthritis Res Ther 14(3):R112
12. Svensson B, Hafstrom I (2011) Effects on joint destruction and remission, bone turnover and lack of influence on atherogenesis: a review of the BARFOT low-dose prednisolone studies on patients with early RA. Clin Exp Rheumatol 29(5 Suppl 68):S63–S67
13. Nam JL, Villeneuve E, Hensor EM et al (2014) Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). Ann Rheum Dis 73(1):75–85
14. Hetland ML, Horslev-Petersen K (2012) The CIMESTRA study: intra-articular glucocorticosteroids and synthetic DMARDs in a treat-to-target strategy in early rheumatoid arthritis. Clin Exp Rheumatol 30(4 Suppl 73):S44–S49
15. de Jong PH, Hazes JM, Barendregt PJ et al (2013) Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial. Ann Rheum Dis 72(1):72–78
16. Bakker MF, Jacobs JW, Welsing PM et al (2012) Low-dose prednisone inclusion in a methotrexate-based, tight control strategy for early rheumatoid arthritis: a randomized trial. Ann Intern Med 156(5):329–339
17. Gossec L, Paternotte S, Aanerud GJ et al (2011) Finalisation and validation of the rheumatoid arthritis impact of disease score, a patient-derived composite measure of impact of rheumatoid arthritis: a EULAR initiative. Ann Rheum Dis 70(6):935–942
18. Lautenschlaeger J, Mau W, Kohlmann T et al (1997) [Comparative evaluation of a German version of the Health Assessment Questionnaire and the Hannover Functional Capacity Questionnaire] German. Z Rheumatol 56(3):144–155
19. Boyd TA, Bonner A, Thorne C et al (2013) The relationship between function and disease activity as measured by the HAQ and DAS28 varies over time and by Rheumatoid factor status in early inflammatory arthritis (EIA). Results from the CATCH Cohort. Open Rheumatol J 7:58–63
20. Combe B, Rincheval N, Benessiano J et al (2013) Five-year favorable outcome of patients with early rheumatoid arthritis in the 2000s: data from the ESPOIR cohort. J Rheumatol 40(10):1650–1657
21. Svensson B, Andersson ML, Bala SV, Forslind K, Hafstrom I (2013) Long-term sustained remission in a cohort study of patients with rheumatoid arthritis: choice of remission criteria. BMJ Open 3(9):e003554
22. McKeown E, Bykerk VP, De Leon F et al (2012) Quality assurance study of the use of preventative therapies in glucocorticoid-induced osteoporosis in early inflammatory arthritis: results from the CATCH cohort. Rheumatology (Oxford) 51(9):1662–1669
23. Cardiel MH, Pons-Estel BA, Sacnun MP et al (2012) Treatment of early rheumatoid arthritis in a multinational inception cohort of Latin American patients: the GLADAR experience. J Clin Rheumatol 18(7):327–335
24. Wassenberg S, Rau R, Zeidler H (2011) A dose of only 5 mg prednisolone daily retards radiographic progression in early rheumatoid arthritis-the low-dose prednisolone trial. Clin Exp Rheumatol 29(5 Suppl 68):S68–S72
25. Buttgereit F, Mehta D, Kirwan J et al (2013) Low-dose prednisone chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2). Ann Rheum Dis 72(2):204–210